CDKN2B expression and subcutaneous adipose tissue expandability: Possible influence of the 9p21 atherosclerosis locus

Per-Arne Svensson a,1, Björn Wahlstrand a,1, Maja Olsson a, Philippe Froguel b, Mario Falchi b, Richard N. Bergman c, Philip G. McTernan d, Thomas Hedner e, Lena M.S. Carlsson a, Peter Jacobson a,*

a Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Sweden
b Department of Genomics of Common Disease, School of Public Health, Imperial College London, UK
c Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
d Division of Metabolic and Vascular Health, Warwick Medical School, University of Warwick, Coventry, UK

A B S T R A C T

Risk alleles within a gene desert at the 9p21 locus constitute the most prevalent genetic determinant of cardiovascular disease. Previous research has demonstrated that 9p21 risk variants influence gene expression in vascular tissues, yet the biological mechanisms by which this would mediate atherosclerosis merits further investigation. To investigate possible influences of this locus on other tissues, we explored expression patterns of 9p21-regulated genes in a panel of multiple human tissues and found that the tumor suppressor CDKN2B was highly expressed in subcutaneous adipose tissue (SAT). CDKN2B expression was regulated by obesity status, and this effect was stronger in carriers of 9p21 risk alleles. Covariation between expression of CDKN2B and genes implemented in adipogenesis was consistent with an inhibitory effect of CDKN2B on SAT proliferation. Moreover, studies of postprandial triacylglycerol clearance indicated that CDKN2B is involved in down-regulation of SAT fatty acid trafficking. CDKN2B expression in SAT correlated with indicators of ectopic fat accumulation, including markers of hepatic steatosis. Among genes regulated by 9p21 risk variants, CDKN2B appears to play a significant role in the regulation of SAT expandability, which is a strong determinant of lipotoxicity and therefore might contribute to the development of atherosclerosis.

1. Introduction

Manifestations of atherosclerosis such as myocardial infarction and stroke are leading causes of death worldwide [1]. Beside environmental factors including lifestyle, the risk of cardiovascular disease (CVD) is also influenced by genetic variation, and several genomic regions have been linked to CVD [2]. The strongest of these is located on chromosome 9p21, where single-nucleotide polymorphisms (SNPs) located within a 53-kilobase interval have shown consistent and strong association with CVD [3–7].

The 9p21 locus confers CVD risk through a mechanism which appears to be independent from conventional risk factors, including dyslipidaemia, hypertension, and impaired glucose metabolism [5,8–10]. However, a recent study indicated that the effect of risk variants is modified by diet [11].

Most of the CVD-associated SNPs within the 9p21 locus are located in a so-called gene desert – a genomic region devoid of protein-coding genes. Recent studies of gene expression in vascular tissues or peripheral mononuclear blood cells demonstrate that the 9p21 disease variants may be involved in the regulation of nearby genes, including cyclin-dependent kinase inhibitor 2A/B (CDKN2A), CDKN2B and antisense noncoding RNA in the INK4 locus (ANRIL) [12–17]. However, the reported associations between risk variants and gene expression appear somewhat conflicting, as reviewed by Cunnington & Keavney [18]. One reason for this may be that the CVD risk SNPs affect the expression of ANRIL, which in turn may affect expression of other nearby genes via epigenetic mechanisms [19].

---

CDKN2B, cardiovascular disease; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; CDKN2A/B, cyclin-dependent kinase inhibitor 2A/B; ANRIL, antisense noncoding RNA in the INK4 locus; MTAP, methylthioadenosine phosphorylase; BMI, body mass index; TAG, triacylglycerol.

* Corresponding author. Address: SOS-sekr. Vita stråket 15, S-41345 Göteborg, Sweden.
E-mail address: peter.jacobson@medfak.gu.se (P. Jacobson).

1 P.-A.S. and B.W. are equal first authors.
Although a regulatory role of the 9p21 locus on gene expression in vascular tissues has been found, the biological mechanisms that would link this to human atherosclerosis development are still not fully elucidated. Studies in humans and in mice models have shown that vascular mechanisms, such as smooth muscle cell proliferation [20], response to inflammatory signaling [21] and macrophage phagocytosis [22], may be involved. However, the CVD-associated variants at the 9p21 locus may affect the expression of adjacent genes also in extravascular tissues. We therefore explored the possible regulatory influences of this locus in human tissues not previously studied in this context and subsequently assessed the findings in carefully phenotyped cohorts.

2. Materials and methods

All subjects gave written informed consent prior to inclusion in the study. The studies were conducted in accordance with the Declaration of Helsinki and were approved by the local ethics committees.

2.1. Study populations

The Sibpair study includes 154 Swedish nuclear families recruited via BMI-discordant adult sibling pairs (BMI difference \( \geq 10 \, \text{kg/m}^2 \)) as described previously [23]. Subjects underwent extensive phenotypic examinations. In the current analysis, gene expression data were available for 354 adults (106 males) from 151 families. BMI ranged from 16.9 to 57.5 kg/m² (Supplementary Table II).

Lean and obese women from UK undergoing elective surgery were recruited and abdominal subcutaneous and omental adipose tissue biopsies were obtained [24] (Supplementary Table II). Obese Swedish subjects underwent 18 weeks of caloric restriction by means of very-low calorie diets [25]. Subcutaneous adipose tissue biopsies were taken at baseline, week 8, and week 18 from a subset of 10 subjects (Supplementary Table II).

2.2. DNA microarray analysis

Adipose tissue RNA preparation and microarray analysis (U133 plus 2.0 microarrays, Affymetrix, Santa Clara, CA, USA) were performed as previously described [26].

2.3. Real-time PCR analysis

RNA was reverse transcribed using the High Capacity cDNA RT kit (Applied Biosystems, Foster City, CA, USA). Reagents for real-time PCR analysis of CDKN2B (Hs00793225_m1), LPR10 (Hs00204094_m1), and PPIA (Hs99999904_m1) were purchased from Applied Biosystems and used according to the manufacturer’s protocol.

2.4. Genotyping

DNA was isolated from whole blood and genotyping of the rs10757278 and rs2383207 was performed using the TaqMan®-based system (Applied Biosystems) and assays (C_11841860_10 and C_15789010_10). Successful genotypes were obtained from 95.2% for rs10757278 and 96.7% for rs2383207.

2.5. Body composition

A subset (\( n = 137 \)) from the Sibpair study underwent computed tomography measurements of body composition. Visceral and subcutaneous fat were estimated from a scan at the level of the iliac crest. Leg subcutaneous and intermuscular fat were estimated at the mid-thigh level. Tissue areas were determined as previously described [27].

2.6. Intravenous glucose tolerance test and biochemistry

Frequent-sampling intravenous glucose tolerance test was performed in the Sibpair cohort for the assessment of insulin sensitivity (SI) and disposition index (DI), and blood biochemistry was performed as previously described [26].

2.7. Postprandial lipid metabolism

Postprandial triacylglycerol (TAG) clearance in subjects of the Sibpair study was measured in serum drawn in the fasting state and hourly for seven hours after ingestion of a standard meal composed of 41.3 g protein (22% of energy content), 46.3 g fat (54%), and 46.8 g carbohydrates (25%), corresponding to 769 kcal. Clearance was expressed as area under the curve, adjusted for fasting value.

2.8. Statistical analysis

Statistical analyses were performed using the SAS software package (v. 9.1.3, SAS Institute Inc, Cary, NC, USA). Quantitative data were transformed towards normal distribution using Box-Cox power transformations. Outliers beyond 3 standard deviations from the trait mean were excluded. Additional statistical analyses are described in the Method supplement.

3. Results

3.1. CDKN2B is highly expressed in adipocytes

The expression of 9p21 positional candidate genes ANRIL, CDKN2A, CDKN2B, and MTAP were analyzed by microarray in a panel of 65 human tissues. The CDKN2B gene showed the highest expression in subcutaneous adipose tissue (SAT) whereas the other positional candidate genes displayed low signals in all tissues investigated (Fig. S1). The tissue distribution pattern of CDKN2B expression was also investigated by real-time PCR in a subset of tissues and cells. In this analysis, the highest expression of CDKN2B was observed in subcutaneous adipocytes (Fig. 1A). In view of the association between obesity and CVD, which is independent of conventional CVD risk factors [28], we pursued the investigation of CDKN2B expression in adipose tissue further.

3.2. Adipose tissue CDKN2B expression varies among fat depots and is regulated by energy balance

Given that different adipose tissue depots have varying influences on the metabolism [29], CDKN2B expression was investigated in paired SAT and omental adipose tissue biopsies (\( n = 10 \)) by microarray. Higher expression in SAT compared to omental adipose tissue was found in both lean (3.2-fold, \( P = 0.004 \)) and obese (2.9-fold, \( P = 0.028 \)) subjects (Fig. 1B). A correlation between BMI and SAT CDKN2B expression was found in the Sibpair study (\( r = 0.46, P = 6.3 \times 10^{-20} \)) (see Fig. 2A). This finding was confirmed by real-time PCR in a small set of SAT and subcutaneous adipocyte samples (Fig. 1C).

Next, we investigated whether CDKN2B expression in SAT is regulated by weight loss following 18 weeks of severe caloric restriction in ten obese individuals. A mean weight loss of 28.4 (range 21.0–38.6) kilograms induced decreased CDKN2B expression (Fig. 1D, \( P = 0.001 \)).
3.3. BMI-dependent association between 9p21 variants and adipose tissue CDKN2B expression

CVD risk alleles at 9p21 locus have been shown to influence CDKN2B expression and therefore the associations between risk alleles of the rs10757278 SNP and CDKN2B expression in SAT were investigated in the Sibpair study. No direct association between expression and risk allele carrier status was found. However, in a model which adjusted for non-independence among relatives, sex, age and BMI, a positive correlation between risk allele carrier status and CDKN2B expression was found ($P = 0.002$). Moreover, risk variant carrier status modified the previously described association between BMI and CDKN2B expression by RT-PCR in subcutaneous adipose tissue at the whole-tissue level and specifically in adipocytes from healthy volunteers. The measurements are the same as in panel A. CDKN2B expression was normalized to reference gene PPIA. Similar results were obtained for the risk allele (G) of rs2383207, both for the main effect ($P = 0.0052$) and for the interaction ($P = 0.048$).

3.4. Inverse relationship between expression of CDKN2B and genes implicated in adipose tissue expandability

The known anti-proliferative effects of CDKN2B [30], its high expression in SAT and its link to obesity suggest that this gene is involved in the regulation of SAT growth and expandability in response to changes in energy balance. We sought further support for this theory using the Sibpair study to examine expression covariation between CDKN2B and genes implemented in various aspects of adipose tissue expandability, such as adipogenesis, proliferation and angiogenesis.

Among the genes whose expression correlated significantly with CDKN2B expression, 259 genes could be classified as having promotive or inhibitory effects on adipose tissue expandability (see Supplementary methods and Supplementary Table I). Aiming to discern a global effect of CDKN2B on these 259 genes, we performed an association analysis between the promotive or inhibitory effects of the genes versus their positive or negative correlation with CDKN2B expression. As shown in Fig. 2B, the majority of promotive genes correlated negatively with CDKN2B, whereas the majority of inhibitory genes correlated positively with CDKN2B. Consistently, there were lower than expected frequencies of promotive genes positively correlated and inhibitory genes negatively correlated with CDKN2B expression ($X^2 = 30.9, P = 2.7 \times 10^{-8}$).

The classical initiator of adipogenesis, peroxisome proliferator-activated receptor gamma [31], was negatively correlated with CDKN2B, whereas adipogenesis inhibitors such as Cyclin D1 [32] and WW domain containing transcription regulator 1 [33] were positively correlated with CDKN2B.
Angiogenesis is essential to adipose tissue growth, and 35 angiogenesis genes were highly expressed in SAT and significantly correlated with CDKN2B expression. Among antiangiogenic genes, thrombospondin 1, caveolin 1 and 2 were positively correlated with CDKN2B. Expression of important proangiogenic genes e.g., angiogenin and vascular endothelial growth factor A, were negatively correlated with CDKN2B expression (Supplementary Table I).

3.5. Increased CDKN2B expression in SAT impedes postprandial lipid clearance

Impairment of adipose tissue growth and lipid accommodation manifests itself as ectopic lipid accumulation. Therefore, we investigated covariation of CDKN2B expression with clinical indicators of a “lipodystrophic” phenotype.

One acute effect of such impairment, which can be studied in the short term, is reduced clearance from serum of lipids derived from the consumption of a meal. We measured postprandial triacylglycerol (TAG) levels following a standardized meal in subjects from the Sibpair study, subdivided into tertiles of SAT CDKN2B expression. The results show that high adipose tissue CDKN2B expression is linked to high postprandial TAG levels (Fig. 2C, \( P = 0.0005 \)). The effect of CDKN2B expression level was independent of BMI, which is a strong determinant of postprandial lipidaemia.

3.6. CDKN2B expression in SAT and ectopic lipid accumulation

Other indicators of lipodystrophy or lipotoxicity include the abundance of visceral, intramuscular and hepatic fat, insulin resistance, and impaired pancreatic beta cell function.

In a subset of the Sibpair cohort, we used computed tomography to measure body composition at the iliac crest and mid-thigh levels. These levels were chosen to obtain estimates of abdominal subcutaneous vs. visceral adipose tissue (VAT) and extremity subcutaneous vs. intermuscular adipose tissue, respectively. CDKN2B expression was positively correlated with the majority of these adipose tissue measurements (Table 1, model 1). Moreover, the VAT/SAT ratio and the amount of SAT in the thigh correlated significantly to CDKN2B expression even after adjustment for BMI (Table 1, model 2).

Using serum alanine aminotransferase (S-ALAT) as a marker [34], we found evidence of a relationship between CDKN2B expression in SAT and hepatic steatosis, since S-ALAT was positively correlated with CDKN2B expression, also after BMI adjustment.
We found substantially higher expression of the SAT CDKN2B expression in adipose tissue. More importantly, the risk variants modified the correlation between BMI and CDKN2B expression, suggesting that the expandability of SAT in risk allele carriers is reduced. Visel et al. [38] showed that deletion of a 70-kilobase noncoding region on mouse chromosome 4, orthologous to the human 9p21 CVD risk interval resulted in reduced Cdkн2a and Cdkн2b expression. Compared to the wild type, a faster weight gain was seen in mice lacking this region, whereas a difference in aortic fatty-lesions after high fat diet could not be shown. In view of our findings, the results may be interpreted in terms of reduced lipotoxicity due to loss of Cdkн2b-mediated inhibition of SAT. However, a recent study showed that Cdkн2b deficient mice on an ApοE deficient background develop more atherosclerosis compared to ApοE deficient mice with an intact Cdkн2b gene [22].

Our study lacked statistical power to assess direct associations between CVD risk alleles and lipotoxicity phenotypes. A large study on two independent human cohorts, showed significant interaction between unhealthy diet and 9p21 risk alleles on CVD, whereas carrier status did not affect risk in subjects on healthier diet [11]. Those results are consistent with ours, which showed higher postprandial TAG in subjects with high CDKN2B expression, which in turn was higher in 9p21 risk allele carriers. Relevant to our findings and their proposed contribution to CVD risk, postprandial lipid dysmetabolism has been shown to independently predict CVD [39–41]. The reason that the CVD risk of the 9p21 locus have been shown to be independent of dyslipidaemia may be due to that only fasting blood lipid levels have been investigated.

Based on our findings, we propose that CDKN2B is involved in the regulation of SAT in response to changes in energy balance. This study suggests that 9p21 risk alleles contribute to CVD risk indirectly via inhibition of adipogenesis and adipose tissue expandability which may promote ectopic fat accumulation.

4. Discussion

The mechanism that links regulatory sequence variants within the 9p21 gene desert with CVD has in recent years been intensely investigated. Studies have suggested mechanisms in vascular tissue that may contribute to this link [20–22]. Our study suggests a new possible route how the 9p21 locus may affect CVD development via alteration in adipose tissue CDKN2B expression.

We found that CDKN2B is highly expressed in SAT, and its expression shows covariation with energy balance (higher expression in obese subjects and down-regulated expression during caloric restriction-induced weight-loss). Considering the capability of adipose tissue to expand and retract throughout life, it is not surprising that a gene implemented in cell cycle regulation is variably expressed in this tissue. In line with this, we observed a correlation pattern between CDKN2B expression and expression of genes involved in adipose tissue expandability, suggesting that CDKN2B has an inhibitory effect on adipogenesis and SAT expandability. A recent study by Horswell et al. has provided direct experimental support to the hypothesis that CDKN2B is important for adipogenesis. They show that knock-down of Cdkn2b expression in a mouse adipocyte cell line results in increased adipogenesis [35]. Moreover, we found substantially higher CDKN2B expression in subcutaneous than in visceral adipose tissue, suggesting a larger restraint on the proliferative capacity and adipogenesis of the former compared to the latter, which might contribute to their altered relative abundances.

Inadequate SAT expandability and fat storage capacity is the disease-causing mechanism behind lipodystrophy syndromes. It has been proposed that the dysmetabolic consequences of severe obesity are partly attributable to “acquired lipodystrophy” which develops as the adipocytes reach their maximal capacity to accommodate dietary lipids, causing lipid accumulation in visceral fat depots and non-adipose tissues [36]. McQuaid et al. observed that obese men, despite substantially greater adipose tissue mass, showed depressed adipose tissue fat storage capacity compared with lean controls [37].

Several studies have investigated the link between CVD risk SNPs at the 9p21 locus and expression of CDKN2B in vascular tissue and leukocytes. However, the results from these studies are conflicting [18]. This may partially be due to the risk variant influence on the expression of ANRIL, in turn which may affect CDKN2B expression via epigenetic mechanisms [19]. In addition, confounders such as age and BMI were not always accounted for. We found a BMI dependent association between risk allele carrier status and CDKN2B expression in adipose tissue. More importantly, the risk variants modified the correlation between BMI and CDKN2B expression, suggesting that the expandability of SAT in risk allele carriers is reduced. Visel et al. [38] showed that deletion of a 70-kilobase noncoding region on mouse chromosome 4, orthologous to the human 9p21 CVD risk interval resulted in reduced Cdkн2a and Cdkн2b expression. Compared to the wild type, a faster weight gain was seen in mice lacking this region, whereas a difference in aortic fatty-lesions after high fat diet could not be shown. In view of our findings, the results may be interpreted in terms of reduced lipotoxicity due to loss of Cdkн2b-mediated inhibition of SAT. However, a recent study showed that Cdkн2b deficient mice on an ApοE deficient background develop more atherosclerosis compared to ApοE deficient mice with an intact Cdkн2b gene [22].
[5] R. McPherson, A. Pertsemidlis, N. Kavaslar, A. Stewart, et al., A common allele on chromosome 9 associated with coronary heart disease, Science 316 (2007) 1488–1491.

[6] G.E. Palomaki, S. Melillo, L.A. Bradley, Association between 9p21 genomic markers and heart disease: a meta-analysis, JAMA 303 (2010) 648–656.

[7] N.J. Samani, J. Erdmann, A.S. Hall, C. Hengstenberg, et al., Genomewide association analysis of coronary artery disease, N. Engl. J. Med. 357 (2007) 443–455.

[8] N.P. Paynter, D.J. Chasman, J.E. Buring, D. Shiffman, et al., Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3, Ann. Intern. Med. 150 (2009) 63–72.

[9] H. Schunkert, A. Gotz, P. Braund, R. McGinnis, et al., Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease, Circulation 117 (2008) 1675–1684.

[10] R. Wahlstrand, M. Orho-Melander, L. Delling, S. Kjeldsen, et al., The myocardial infarction associated CDKN2A/CDKN2B locus on chromosome 9p21 is associated with stroke independently of coronary events in patients with hypertension, J. Hypertens. 27 (2009) 769–773.

[11] B. Wahlstrand, M. Orho-Melander, L. Delling, S. Kjeldsen, et al., The effect of chromosome 9p21 variants on cardiovascular disease may be modified by dietary intake: evidence from a case/control and a prospective study, PLoS Med. 8 (2011) e1001060.

[12] O. Jarinova, A.F. Stewart, R. Roberts, G. Wells, et al., Association between 9p21 genomic markers and heart disease: a meta-analysis of the association between chromosome 9p21 and heart disease, N. Engl. J. Med. 357 (2007) 611–617.

[13] E.D. Rosen, P. Sarraf, A.E. Troy, G. Bradwin, et al., PPAR gamma is required for atherosclerotic plaque, Atherosclerosis 150 (2000) 167–177.

[14] L.M. Holdt, F. Beutner, M. Scholz, S. Gielen, et al., ANRIL expression is associated with atherosclerosis risk at chromosome 9p21, Arterioscler. Thromb., Vasc. Biol. 30 (2010) 620–627.

[15] K. Omagari, R. Takamura, S. Matsutake, M. Ichimura, et al., Serum alanine transaminase concentration as a predictive factor for the development or regression of fatty liver, J. Clin. Biochem. Nutr. 49 (2011) 553–560.

[16] S.D. Horswell, L.G. Fryer, C.E. Hutchison, D. Zindrou, et al., CDKN2B expression degradation and promotes breast cell proliferation and tumorigenesis, Carcinogenesis 33 (2012) 59–67.

[17] K. Omagari, R. Takamura, S. Matsutake, M. Ichimura, et al., Serum alanine aminotransferase concentration as a predictive factor for the development or regression of fatty liver, J. Clin. Biochem. Nutr. 49 (2011) 553–560.

[18] L. Heilbronn, S.R. Smith, E. Ravussin, Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, Int. J. Obes. Relat. Metab. Disord. 28 (Suppl. 4) (2004) S12–S21.

[19] C. Wang, N. Pattabiraman, J.N. Zhou, M. Fu, et al., Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation, Mol. Cell. Biol. 23 (2003) 6159–6173.

[20] P.-A. Svensson et al. / Biochemical and Biophysical Research Communications 446 (2014) 1126–1131

[21] P. Krimpenfort, A. Ijpenberg, J.Y. Song, M. van der Valk, et al., P15Ink4a is a critical tumour suppressor in the absence of p16Ink4a, Nature 448 (2007) 943–946.

[22] B.G. Nordestgaard, M. Benn, P. Schnohr, A. Tybjaerg-Hansen, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women, JAMA 298 (2007) 299–308.

[23] A. Visel, Y. Zhu, D. May, V. Afzal, et al., Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice, Nature 464 (2010) 409–412.

[24] M. McPherson, A. Pertsemidlis, N. Kavaslar, A. Stewart, et al., A common allele on chromosome 9 associated with coronary heart disease, Biochem. Biophys. Res. Commun. 382 (2009) 309–314.